Clinical Trial Update: Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study of seribantumab in adults with NRG1 gene fusion-positive advanced solid tumors has been terminated, with results posted in April 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Head and Neck Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• Seribantumab (seribantumab)

Snippet

Sponsor: Elevation Oncology | Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2025-04-03